false 0001422142 0001422142 2022-08-10 2022-08-10





Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 10, 2022




(Exact name of registrant as specified in its charter)




Delaware   001-38560   61-1547850
(State or other jurisdiction
of incorporation)
File Number)
  (I.R.S. Employer
Identification No.)


17383 Sunset Boulevard, Suite A250
Pacific Palisades, California
(Address of principal executive offices)   (Zip code)

Registrant’s telephone number, including area code: (424) 744-8055

(Former name or former address, if changed since last report.)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class




Name of each exchange
on which registered

Common Stock, par value $0.0001 per share   AADI   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 2.02. Results of Operations and Financial Condition.

On August 10, 2022, Aadi Bioscience, Inc. issued a press release announcing its financial results for the fiscal quarter ended June 30, 2022. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits




99.1    Press Release, dated August 10, 2022
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 10, 2022


/s/ Neil Desai, Ph.D.

Neil Desai, Ph.D.
President and Chief Executive Officer
EX-99.1 2 d349452dex991.htm EX-99.1 EX-99.1

Exhibit 99.1



Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update

FYARRO® (nab-sirolimus) net product sales reached $3.4 million for the second quarter of 2022

PRECISION 1 Phase 2 tumor-agnostic registration-directed trial continues enrollment and rapid site activation at major cancer centers and large community networks; preliminary data expected 1H23

Conference call to be held today at 8:30 am EDT

LOS ANGELES, CA, August 10, 2022 – Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today provided a corporate update and announced financial results for the second quarter of 2022.

“We continue to progress in key areas after our first full quarter following FYARRO’s launch. We are excited to see FYARRO reaching more patients through continued account adoption and steady growth in overall sales,” said Neil Desai, Ph.D., Founder, President and Chief Executive Officer of Aadi. “We are also encouraged by the progress on our tumor agnostic PRECISION 1 trial targeting TSC1 and TSC2 inactivating alterations which continues to ramp up, with activation of additional clinical trial sites and patient enrollment. We anticipate providing preliminary data on a meaningful number of patients in this trial during the first half of 2023. In addition, we continue to evaluate strategies for new clinical indications of nab-sirolimus either as single agent or in combination with other targeted therapies with the potential for new programs as early as 2023.”

Corporate Updates for the Second Quarter 2022



FYARRO net product sales for the three months ended June 30, 2022 were $3.4 million, the first full quarter of sales following the product launch late in the first quarter.



A product-specific permanent J-code (J9331) for FYARRO from Centers for Medicare and Medicaid Services (CMS) became effective on July 1, 2022. This code is expected to further facilitate reimbursement for FYARRO.



The Company announced its addition to both the U.S. small cap Russell 2000® Index and broad-market Russell 3000® Index at the conclusion of the 2022 Russell indexes annual reconstitution, which captures the 4,000 largest U.S. stocks, ranking them by total market capitalization.



Partnerships with prominent next generation sequencing (NGS) providers and leaders in genomic testing and profiling was announced during the quarter, which included Foundation Medicine, Tempus and others. The Company is leveraging these partnerships to expedite patient identification and recruitment for the ongoing PRECISION 1 trial of nab-sirolimus in patients harboring tumors with inactivating alterations in TSC1 or TSC2 genes, and is making significant progress toward opening the trial in at least 20 major cancer centers and upward of 120 treatment sites in the U.S. by the end of 2022.




A poster presentation entitled, “nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program” was presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The data included exploratory biomarker results reported from the final analysis of mTOR inhibitor-naïve advanced malignant PEComa patients treated with nab-sirolimus in the Advanced Malignant PEComa Trial (AMPECT) trial as well as an analysis of prior mTOR inhibitor exposed advanced malignant PEComa patients treated with nab-sirolimus in the Expanded Access Program (EAP) through June 2021. Findings from both the AMPECT study and the EAP showed greater clinical benefit in patients with TSC1 or TSC2 inactivating alterations who received nab-sirolimus compared to all evaluable patients, regardless of prior mTOR inhibitor exposure.



The Company sponsored a poster at the Annual Meeting of the American Association for Cancer Research (AACR) which indicated the incidence of advanced cancer patients carrying TSC1 or TSC2 inactivating gene alterations numbered approximately 12,000 annually in the US, thus potentially rendering these patients eligible for nab-sirolimus therapy.

Second Quarter 2022 Financial Results



Cash and cash equivalents on June 30, 2022 were $118.7 million, compared to $149.0 million as of December 31, 2021. Based on current plans, the Company expects cash and cash equivalents to fund operations into 2024.



Total revenue for the quarter ended June 30, 2022 was $3.4 million resulting from sales of FYARRO.



In the second quarter of 2022, the Company recorded a non-cash impairment charge of $3.7 million to write-off the value of an intangible asset related to the Gossamer license agreement with the Company’s predecessor, Aerpio.



Net loss for the three months ended June 30, 2022 was $18.3 million compared to $1.5 million for the three months ended June 30, 2021.

Conference Call Information

The Aadi management team is hosting a conference call and webcast today at 8:30 am ET (5:30 am PT) to provide a corporate update and discuss results for the second quarter of 2022.

Participants may access a live webcast of the call on the “Investors & News” page of the Aadi Biosciences website at aadibio.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company’s website for at least 30 days.




FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

About the PRECISION 1 Trial

The PRECISION 1 trial is a multi-center, open-label, tumor-agnostic pivotal study, of nab-sirolimus designed as a basket trial that will evaluate approximately 120 adult and adolescent patients with solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes. The trial will have two independent arms of 60 patients each to separately evaluate patients with either TSC1 or TSC2 inactivating alterations. Aadi has received Fast Track designation to evaluate nab-sirolimus in this indication from the FDA. The first patient in the PRECISION 1 trial was dosed in March 2022.

About Aadi Bioscience

Aadi is a biopharmaceutical company focused on precision therapies for genetically defined cancers. Aadi’s primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. In November 2021, Aadi received FDA approval for FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), and in February 2022 Aadi announced the commercial launch of FYARRO in this indication.

Based on exploratory data from AMPECT, Aadi’s registrational study supporting approval in malignant PEComa, and following a pre-IND meeting with the FDA, Aadi has initiated PRECISION 1, a Phase 2 tumor-agnostic registration-intended trial in mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. More information on Aadi’s development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.

Forward-Looking Statements

This press release contains certain forward-looking statements regarding the business of Aadi Biosciences that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company’s current beliefs and expectations; plans and potential for success relating to commercializing FYARRO; expectations regarding the beneficial characteristics, safety, efficacy and therapeutic effects of FYARRO; plans related to further development and manufacturing of FYARRO; pricing and reimbursement of FYARRO; the rate and degree of market acceptance of FYARRO; anticipated reception of FYARRO in the physician community; the clinical results and timing of additional clinical trials, including the registration-directed trial in patients harboring TSC1 or TSC2 inactivating alterations; the timing and likelihood of regulatory filings and approvals of FYARRO, including in potential additional indications and potential filings in additional jurisdictions; and the sufficiency of our existing capital resources and the expected timeframe to fund our future operating expenses and capital expenditure requirements. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, those associated with the



ability to successfully commercialize FYARRO; risks related to reimbursement and pricing of FYARRO; uncertainties associated with the clinical development and regulatory approval of FYARRO in additional indications, including potential delays in the commencement, enrollment and completion of clinical trials for additional indications; the risk that unforeseen adverse reactions or side effects may occur in the course of commercializing, developing and testing FYARRO; risks associated with the failure to realize any value from FYARRO in light of inherent risks and difficulties involved in successfully bringing product candidates to market; risks related to Aadi’s estimates regarding future expenses, capital requirements and need for additional financing; and risks related to the impact of the COVID-19 pandemic on Aadi’s operations, the biotechnology industry and the economy generally.

Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, including under the caption “Item 1. Risk Factors” and in Aadi’s subsequent Quarterly Reports on Form 10-Q filed on May 12, 2022 and August 10, 2022, and elsewhere in Aadi’s reports and other documents that Aadi has filed, or will file, with the SEC from time to time and available at www.sec.gov.

All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Aadi undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.


Marcy Graham






(In thousands)



     June 30,     December 31,  
     2022     2021  



Current assets:


Cash and cash equivalents

   $  118,737     $  148,989  

Accounts receivable, net

     2,063     —  


     727     —  

Prepaid expenses and other current assets

     2,808     2,283







Total current assets

     124,335     151,272

Property and equipment, net

     357     57

Operating lease right-of-use  assets

     1,653     557

Intangible asset, net

     —       3,811

Other assets

     2,291     2,213







Total assets

   $  128,636     $  157,910  







Liabilities and stockholders’ equity


Current liabilities:


Accounts payable

   $  3,619     $  6,439  

Accrued liabilities

     8,653     8,703

Operating lease liabilities, current portion

     324     131







Total current liabilities

     12,596     15,273

Other liabilities

     109     —  

Operating lease liabilities, net of current portion

     1,444     474

Due to licensor

     5,757     5,757







Total liabilities

     19,906     21,504

Stockholders’ equity:


Preferred stock

     —       —  

Common stock

     2     2

Additional paid-in capital

     283,539     279,089

Accumulated deficit

     (174,811     (142,685







Total stockholders’ equity

     108,730     136,406







Total liabilities and stockholders’ equity

   $  128,636     $  157,910  











(In thousands, except shares and earnings per share amounts)



     Three months ended     Six months ended  
     June 30,     June 30,  
     2022     2021     2022     2021  



Product sales, net

   $  3,437     $ —     $  5,744     $ —  

Grant revenue

       —         120













Total Revenue

     3,437     —       5,744     120













Operating expenses


Selling, general and administrative

     10,006     830     19,154     1,393

Research and development

     7,726     3,045     14,519     6,689

Cost of goods sold

     341     —       520     —  

Impairment of intangible asset

     3,724     —       3,724     —  













Total operating expenses

     21,797     3,875     37,917     8,082













Loss from operations

     (18,360     (3,875     (32,173     (7,962

Other income (expense)


Change in fair value of convertible promissory notes

     —       2,371       —       1,206  

Gain upon extinguishment of debt

     —       196       —       196  

Interest income

     158     1     171     1

Interest expense

     (58     (227     (115     (451













Total other income, net

     100     2,341     56     952













Loss before income tax expense

     (18,260     (1,534     (32,117     (7,010

Income tax expense

     (9     (2     (9     (2













Net loss

   $ (18,269   $ (1,536   $ (32,126   $ (7,012













Net loss per share attributable to common stockholders, basic and diluted

   $ (0.87   $ (0.60   $ (1.53   $ (2.76













Weighted average number of common shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted

     20,970,459     2,542,358     20,942,804     2,542,358














EX-101.SCH 3 aadi-20220810.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 aadi-20220810_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 aadi-20220810_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g349452snap1.jpg GRAPHIC begin 644 g349452snap1.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information
Aug. 10, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001422142
Document Type 8-K
Document Period End Date Aug. 10, 2022
Entity Registrant Name AADI BIOSCIENCE, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-38560
Entity Tax Identification Number 61-1547850
Entity Address, Address Line One 17383 Sunset Boulevard
Entity Address, Address Line Two Suite A250
Entity Address, City or Town Pacific Palisades
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90272
City Area Code (424)
Local Phone Number 744-8055
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol AADI
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
XML 8 d349452d8k_htm.xml IDEA: XBRL DOCUMENT 0001422142 2022-08-10 2022-08-10 false 0001422142 8-K 2022-08-10 AADI BIOSCIENCE, INC. DE 001-38560 61-1547850 17383 Sunset Boulevard Suite A250 Pacific Palisades CA 90272 (424) 744-8055 false false false false Common Stock, par value $0.0001 per share AADI NASDAQ true true EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d349452d8k.htm aadi-20220810.xsd aadi-20220810_lab.xml aadi-20220810_pre.xml d349452dex991.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d349452d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d349452d8k.htm" ] }, "labelLink": { "local": [ "aadi-20220810_lab.xml" ] }, "presentationLink": { "local": [ "aadi-20220810_pre.xml" ] }, "schema": { "local": [ "aadi-20220810.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "aadi", "nsuri": "http://www.aadi.com/20220810", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d349452d8k.htm", "contextRef": "duration_2022-08-10_to_2022-08-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d349452d8k.htm", "contextRef": "duration_2022-08-10_to_2022-08-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.aadi.com//20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001193125-22-216844-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-216844-xbrl.zip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end